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ILC3s integrate glycolysis and mitochondrial
production of reactive oxygen species to fulfill
activation demands
Blanda Di Luccia1, Susan Gilfillan1, Marina Cella1, Marco Colonna1, and Stanley Ching-Cheng Huang1,2
Group 3 innate lymphoid cells (ILC3s) are the innate counterparts of Th17 that require the transcription factor RORγt for
development and contribute to the defense against pathogens through IL-22 and IL-17 secretion. Proliferation and effector
functions of Th17 require a specific mTOR-dependent metabolic program that utilizes high-rate glycolysis, while
mitochondrial lipid oxidation and production of reactive oxygen species (mROS) support alternative T reg cell differentiation.
Whether ILC3s employ a specific metabolic program is not known. Here, we find that ILC3s rely on mTOR complex 1 (mTORC1)
for proliferation and production of IL-22 and IL-17A after in vitro activation and Citrobacter rodentium infection. mTORC1
induces activation of HIF1α, which reprograms ILC3 metabolism toward glycolysis and sustained expression of RORγt.
However, in contrast to Th17, ILC3 activation requires mROS production; rather than inducing an alternative regulatory fate as
it does in CD4 T cells, mROS stabilizes HIF1α and RORγt in ILC3s and thereby promotes their activation. We conclude that
ILC3 activation relies on a metabolic program that integrates glycolysis with mROS production.
Introduction
Group 3 innate lymphoid cells (ILC3s) are innate counterparts of
T helper 17 cells (Th17s; Eberl et al., 2015; Klose and Artis, 2016;
Colonna, 2018). They require retinoic acid receptor–related or-
phan nuclear receptor γt (RORγt) for development and secrete
IL-22 and IL-17. Human ILC3s express the markers NKp44 and
CCR6 and preferentially produce IL-22. Several subsets of mouse
ILC3s are distinguished based on the expression of cell surface
CCR6 and NKp46 as well as the transcription factor T-bet
(Diefenbach et al., 2014). CCR6+NKp46−T-bet− ILC3s secrete
both IL-22 and IL-17A, whereas CCR6−NKp46−T-bet+ ILC3s and
CCR6−NKp46+T-bet+ ILC3s primarily secrete IL-22. ILC3s are
most abundant in the gastrointestinal tract, where they con-
tribute to mucosal barrier integrity and resistance to bacterial
insults, such as Citrobacter rodentium infection (Satoh-Takayama
et al., 2008; Zheng et al., 2008; Sonnenberg et al., 2011; Muñoz
et al., 2015; Song et al., 2015; Rankin et al., 2016). Furthermore,
ILC3 production of IL-17 supports antifungal and antiviral re-
sponses (Gladiator et al., 2013; Hernández et al., 2015). However,
inappropriate activation of ILC3s may contribute to inflamma-
tory bowel disease (IBD) and cancer. Many DNA polymorphisms
associated with IBD impact genes expressed in ILC3s as well as
Th17s (Jostins et al., 2012; Björklund et al., 2016; Koues et al.,
2016). Moreover, ILC3s cause gastrointestinal pathology in
mouse models of IBD and cancer (Kirchberger et al., 2013; Song
et al., 2015; Pearson et al., 2016).
Although ILC3 and Th17 functions largely overlap, the two are
differentially regulated, since Th17 cytokine secretion is trig-
gered through the TCR, while ILC3s respond to specific cyto-
kines and other soluble factors in the tissue microenvironment
(Bando and Colonna, 2016; Huntington et al., 2016). Metabolism
plays a key role in regulation in Th17s, which rely on a marked
increase in aerobic glycolysis for energy and biosynthetic pre-
cursors (Wang and Green, 2012; Chang et al., 2013; Pearce et al.,
2013; Buck et al., 2015). This specific metabolic program is
controlled by mechanistic target of rapamycin (mTOR) and its
related complex 1 (mTORC1; Pollizzi and Powell, 2014; Jones and
Pearce, 2017), which induce expression of the transcription
factor hypoxia-inducible factor 1α (HIF1α). HIF1α orchestrates
glycolysis (Düvel et al., 2010) and, in addition, directly promotes
the transcription of RORγt (Dang et al., 2011; Shi et al., 2011). In
contrast to Th17s, T regulatory (T reg) cells exact less energy
from glycolysis and rely on an alternative metabolic program
that requires mitochondrial oxidation of lipids and pyruvate
(Delgoffe et al., 2009, 2011; Michalek et al., 2011; Gerriets et al.,
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2015; Newton et al., 2016). Mitochondrial metabolism results in
the production of mitochondrial ROS (mROS) that attenuate
glycolysis by inhibiting pyruvate dehydrogenase kinase, a key
checkpoint of glycolysis (Gerriets et al., 2015).
To determine whether the metabolic program regulating
ILC3s parallels that of Th17s, we examined the impact of the
mTORC1-HIF1α axis on ILC3s at steady state, after in vitro
stimulation with cytokines and following in vivo activation by
bacterial infection. Using conditional mTORC1 (Rptor) knockout
mice and mTORC1-HIF1α pharmacological inhibitors, we dem-
onstrated a major role for the mTORC1-HIF1α axis in sustaining
ILC3 numbers, proliferation, and cytokine secretion through
induction of both glycolysis and RORγt expression. However, in
contrast to Th17s, ILC3 activation also markedly increased mi-
tochondrial respiration and generation of mROS, which con-
solidated ILC3 glycolysis, proliferation, and effector functions
rather than inducing an alternative cell fate. ILC3 reliance on
both glycolysis and mROS was conserved in humans. These re-
sults reveal an unanticipated metabolic regulation of ILC3s,
which integrate glycolysis and mROS production to fulfill the
metabolic demands needed for activation.
Results and discussion
RptorΔRorc mice have reduced ILC3 numbers at steady state
To determine whether ILC3s rely on mTOR signaling for meta-
bolic adaptation to environmental signals, we crossed mice in
which the gene for the mTORC1 subunit Raptor is flanked by
loxP sites (Rptorfl/fl) with mice expressing a BAC transgene in
which the RORγt promoter drives the Cre recombinase (Rorc-
Cre). In these conditional knockout mice (called RptorΔRorc mice
hereafter), the Raptor gene is deleted in ILC3s as well as in all
T cells, because RORγt is transiently expressed during thymic
T cell development (Eberl and Littman, 2004). RptorΔRorc mice
had significantly fewer small intestinal RORγt+ ILC3s, including
the CCR6+NKp46−, NKp46−CCR6−, and NKp46+CCR6− subsets,
than did Rptorfl/fl mice (Fig. 1, A–C). Additionally, the residual
ILC3s in RptorΔRorc mice produced relatively little IL-17A and IL-
22 ex vivo in response to IL-1β plus IL-23 (Fig. 1 D). In contrast to
the marked phenotypic changes noted in ILC3s, NK1.1+Eomes−
ILC1s and NK1.1+Eomes+ conventional natural killer (cNK) cell
numberswere comparable in RptorΔRorc andRptorfl/flmice (Fig. 1 E).
Thus, mouse intestinal ILC3s require mTORC1 signaling for
development and function. This result is further corroborated
by the demonstration that deletion of mTORC1 in NKp46+ cells
reduces the number of NKp46+ ILC3s, among others (Marçais
et al., 2014).
Inhibition of mTORC1 signaling impairs the ILC3 response to
bacterial infection
We next sought to determine whether mTORC1 deficiency im-
pacts the ILC3 response to intestinal bacterial infection in vivo.
Since RptorΔRorc mice lack the mTORC1 complex in both ILC3s
and T cells, we generated Rag1−/− × Rptorfl/fl and Rag1−/− ×
RptorΔRorc animals, in which ILC3s are the only source of IL-22
and IL-17, and infected mice with C. rodentium by gavage for 7 d.
We also treated Rag1−/− mice with rapamycin (Rapa) by i.p.
injection to inhibit mTORC1 or with DMSO vehicle, then infected
them with C. rodentium (Fig. S1 A). Uninfected Rag1−/− mice
treated with Rapa did not show any obvious changes in body
weight and colon or cecum length compared with mice injected
with DMSO vehicle (Fig. S1 B). Upon C. rodentium infection,
Rag1−/− mice lacking mTORC1 in ILC3s or treated with Rapa
showed a significant loss of body weight (Figs. 2 A and S1 C), had
marked reduction of colon and/or cecum length (Figs. 2 B and S1D),
and had fewer lymphocytes within the lamina propria (Figs.
2 C and S1 E) compared with control mice. Moreover, Rag1−/− ×
RptorΔRorc significantly impaired phosphorylation of the
translational regulator S6 kinase (S6K) in lamina propria ILC3s
during the infection (Fig. 2 D). Rag1−/− × RptorΔRorc and Rag1−/−
mice treated with Rapa had a twofold reduction of all ILC3s (Figs.
2 E and S1 F); the remaining ILC3s had less intracellular RORγt
(Figs. 2 F and S1 G) and failed to produce large amounts of IL-17A
and IL-22 during infection (Figs. 2 G and S1 H). Also, we observed
a marked decrease in cNK cells from the Rag1−/− × RptorΔRorc
infected mice (Fig. 2 H), which could be due to the Rag deficiency
that diminished NK cell development and fitness (Karo et al.,
2014). In contrast, inhibition of mTORC1 in ILC3s had no de-
tectable impact on the numbers of NKp46+RORγt− ILC1s (Figs. 2 I
and S1 I) or their production of IFNγ (Figs. 2 J and S1 J). Thus, our
data in Rag1−/− × RptorΔRorc and Rag1−/− mice treated with Rapa
strongly supported that mTORC1 is required to sustain ILC3
numbers, expression of RORγt, and production of IL-17A and IL-
22 during C. rodentium infection and that mTORC1 acts mainly in
a cell-intrinsic fashion.
mTORC1 sustains RORγt expression and cytokine production
through HIF1α
Given that mTORC1 drives anabolic and energetic metabolism,
we next asked: what metabolic changes occur during ILC3 ac-
tivation? We addressed this question in the ILC3 cell line MNK3,
which retains phenotypic and functional features characteristic
of murine primary ILC3s, including production of IL-17A and IL-
22 (Allan et al., 2015). MNK3 cells activated with IL-23 plus IL-
1β took up more extracellular glucose than did resting cells, as
measured by staining with 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino)-2-deoxyglucose (2-NBDG; Fig. 3 A), which suggests
that ILC3 activation requires glucose consumption and glycoly-
sis. Accordingly, restricting glucose by exposing MNK3 cells to
2-deoxy-D-glucose (2-DG) markedly lowered production of IL-
17A and IL-22 (Fig. 3 B). MNK3 activation was not entirely as-
sociated with glycolysis, as we also detected an increase in fatty
acid uptake by tracking the fluorescent long-chain fatty acid
analogue boron-dipyrromethene (Bodipy) FL C16 (Fig. 3 A);
moreover, inhibiting fatty acid oxidation by treatment with
etomoxir (ETO) also curbed production of IL-17A and IL-22
(Fig. 3 B), suggesting that activated MNK3 cells maintain the
capacity to use lipids for fuel. Bodipy staining of activatedMNK3
cells also revealed an increase in intracellular neutral lipid stores
(Fig. 3 A), which may reflect de novo lipogenesis, a metabolic
process also reported to distinguish Th17s from T reg cells (Berod
et al., 2014).
The changes in glucose and fatty acid metabolism noted upon
MNK3 cell activation were associated with mTORC1 triggering,
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as indicated by phosphorylation of twomTORC1 targets, S6K and
the eukaryotic translation initiation factor 4E binding protein
1 (4EBP1; Saxton and Sabatini, 2017), which was blocked by Rapa
(Fig. 3 C). Since mTORC1 drives glycolytic metabolism by acti-
vating transcription of the gene for HIF1α (Düvel et al., 2010), we
further investigated the impact of ILC3 activation on HIF1α ex-
pression. Stimulation of MNK3 cells with IL-1β plus IL-23 in-
duced HIF1α protein expression, which was abolished by Rapa
(Fig. 3 D). Corroborating the role of mTORC1-HIF1α in inducing
glycolysis during ILC3 activation, the HIF1α inhibitors PX-478
(PX) and Rapa were equally effective in limiting MNK3 glucose
transporter 1 (Glut1) expression, glucose uptake, and the
extracellular acidification rate (ECAR), which depends on the
generation of lactic acid, the end product of glycolysis (Fig. 3,
E–G). Altogether, mTORC1-HIF1α–mediated metabolic changes
in activated MNK3 cells resulted in a marked increase in ATP
production compared with unstimulated cells, which was
blocked by Rapa and PX (Fig. 3 H).
In addition to impacting ILC3 metabolism, mTORC1-HIF1α
promoted RORγt expression. Inhibition of mTORC1-HIF1α by
Rapa and PX curtailed the expression of RORγt in primary ILC3s
(Figs. 3 I and S2). This result was consistent with a direct role of
HIF1α in activating the transcription of Rorc previously reported in
Th17 cells (Dang et al., 2011; Shi et al., 2011). Ultimately, inhibition
Figure 1. RptorΔRorc mice have lower numbers of ILC3 at steady state. (A) Gating strategy of ILC3 subsets in RptorΔRorc and Rptorfl/fl small intestine lamina
propria. (B) Percentages of small intestine lamina propria ILC3 expressing RORγt in RptorΔRorc and Rptorfl/fl mice (n = 4). (C) Representative FACS plots and
numbers of CCR6+NKp46−, CCR6−NKp46− and CCR6−NKp46+ of RORγt+ILC3 in RptorΔRorc and Rptorfl/flmice. (D) Fold change in cells producing IL-17A and IL-22
within RORγt+ILC3 stimulated with IL-1β + IL-23 ex vivo (n = 4). (E) Representative FACS plots and numbers of ILC1 (NK1.1+Eomes−) and cNK (NK1.1+Eomes+)
cells in RptorΔRorc and Rptorfl/fl small intestine lamina propria (n = 4). ns, not significant. Data are pooled from two independent experiments (mean ± SEM;
Student’s t test; B–E).
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Figure 2. Inhibition ofmTORC1 signaling impairs ILC3 response to a bacterial infection. (A) Changes (%) in bodyweights of C. rodentium–infected Rag1−/− ×
Rptorfl/fl and Rag1−/− × RptorΔRorc mice (n = 4). (B) Images and lengths of colon and cecum from C. rodentium–infected mice (day 7). (C) Total numbers of
intestinal lymphocytes in C. rodentium–infected Rag1−/− × Rptorfl/fl and Rag1−/− × RptorΔRorc mice (day 7, n = 4). (D–F) Expression of pS6K (D), representative
FACS plots and numbers of RORγt+ ILC3s (E), and expression of RORγt (F) in C. rodentium–infected Rag1−/− × Rptorfl/fl and Rag1−/− × RptorΔRorcmice (day 7, n = 4).
(G) Expression of IL-17A and IL-22 within small intestine ILC3s in C. rodentium–infected mice (day 7, n = 4). (H–J) Numbers of cNK cells (H) and
RORγt−NKp46+ ILC1 (I) and percentages of IFNγ+ ILC1 (J) in C. rodentium–infected Rag1−/− × Rptorfl/fl and Rag1−/− × RptorΔRorc mice (day 7, n = 4). ns, not
significant. Data are from one experiment representative of two independent experiments (mean ± SEM of n = 4; Student’s t test). gMFI, geometric mean
fluorescence intensity.
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Figure 3. mTORC1 maintains RORγt expression and cytokine production through HIF1α. (A) Uptake of 2-NBDG, Bodipy FL C16, and Bodipy in MNK3
unstimulated (Unstim) or stimulated (Stim) with IL-1β + IL-23 for 16 h, measured by flow cytometry. (B) Intracellular content of IL-17A and IL-22 in MNK3
measured by flow cytometry. Cell were unstimulated or stimulated with IL-1β + IL-23 for 6 h, either without or with 2-DG or ETO. (C) Flow cytometry analysis
of phosphorylation of S6K and 4EBP1 in MNK3 unstimulated or stimulated with IL-1β + IL-23 for 16 h without or with Rapa. (D) Expression of HIF1α by flow
cytometry analysis in MNK3 treated as in C. (E and F) Expression of Glut1 (E) and uptake of 2-NBDG (F) measured by flow cytometry in MNK3 stimulated with
IL-1β + IL-23 for 16 h without or with Rapa or PX. (G and H) Basal ECAR (G) and ATP levels (H) in MNK3. Cells were unstimulated (dotted line or Unstim) or
stimulated with IL-1β + IL-23 for 6 h without or with Rapa or PX. RLUs, relative light units. (I) Expression of RORγt in MNK3 stimulated with IL-1β + IL-23 for 6 h
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of mTORC1-HIF1α by PX and Rapa suppressed IL-17A and IL-22
secretion by MNK3 cells (Fig. 3 J) and all subsets of primary in-
testinal ILC3s (Fig. 3 K), as well as proliferation of primary ILC3s
(Fig. 3 L). We conclude that the mTORC1-HIF1α axis sustains ILC3
activation, cytokine production, and proliferation by promoting
both glycolytic metabolism and expression of RORγt.
ILC3 activation relies on mROS
It has been shown that Th17s, while relying on glycolysis, have a
low rate of mitochondrial oxidative metabolism, as HIF1α re-
presses mitochondrial function through pyruvate dehydrogen-
ase kinase (Gerriets et al., 2015). Thus, we next tested whether
this was also the case for ILC3s. However, stimulation of MNK3
cells augmented the mitochondrial oxygen consumption rate
(OCR), which was markedly inhibited by PX and Rapa (Fig. 4 A);
this suggests that the mTORC1-HIF1α pathway activates mito-
chondrial metabolism in MNK3 cells. A consequence of mito-
chondria activity is the production of mROS through the
electron transport chain. Accordingly, increased intracellular
content of mROS was evident in activated MNK3 cells, as mea-
sured by staining for 29,79-dichlorofluorescein diacetate
(DCFDA) and MitoSOX; accumulation of intracellular mROS was
curbed by Rapa, ROS scavengers (N-acetyl cysteine [NAC] and
MitoTEMPO), and the inhibitors of complex I and III, rotenone
(Rot) and antimycin A (Ant; Figs. 4 B and S3 A). Similar results
were observed in mouse intestinal ILC3s stimulated ex vivo with
IL-1β plus IL-23 (Figs. 4 C and S3 A).
Since ROS have been shown to stabilize HIF1α protein by
preventing its hydroxylation by prolyl hydroxylase domain-
containing protein 2 and subsequent proteasomal degradation
(Hamanaka and Chandel, 2010), we further tested the impact of
mROS on HIF1α activity in ILC3s. We found that both NAC and
Rot/Ant treatments curtailed HIF1α expression and also im-
paired RORγt expression in MNK3 cells (Fig. 4, D and E). Cor-
roborating the concept that mROS are important for ILC3
activation, both NAC and Rot/Ant treatment disrupted IL-17A
and IL-22 production (Fig. 4 F) and limited cell division, as as-
sessed by the proliferation marker Ki67 (Fig. 4 G). Similar
changes in RORγt, IL-17A, IL-22, and cell division were observed
in cells treated with a specific mROS inhibitor, MitoTEMPO (Fig.
S3, B–D). We conclude that, upon ILC3 stimulation, mTORC1
signaling activates mitochondrial metabolism and the genera-
tion of mROS, which help prolong HIF1α activity and ultimately
cytokine secretion and proliferation.
Inhibition of succinate dehydrogenase (SDH) impairs mROS
and activation in ILC3
It has been shown that mitochondrial oxidation of succinate by
SDH in macrophages leads to reverse electric transport in
complex I of the electron transport chain, driving the production
of mROS that activate HIF1α (Tannahill et al., 2013; Chouchani
et al., 2014; Mills et al., 2016). Therefore, we tested the impor-
tance of SDH in ILC3 metabolism and function. Following ex-
posure to the SDH inhibitor dimethyl malonate (DMM), ILC3s
had decreased levels of HIF1α and RORγt (Fig. 4, H and I), which
consequently reduced ILC3 glucose uptake and lactate produc-
tion (Fig. S3 E), and failed to proliferate and secrete IL-22 and IL-
17A upon stimulation (Fig. 4, J and K). These results suggest that
activated ILC3s rely on SDH and reverse electron transport for
mROS production and effector functions.
Human ILC3 activation requires mTOR-mediated metabolic
reprogramming
We wanted to know whether activated human ILC3s use a
metabolic program similar to that observed in mice. We sorted
tonsillar CD56+NKp44+CCR6+ ILC3s and stimulated them with a
combination of IL-1β and IL-23 ex vivo. We first assessed the
metabolic changes of human ILC3s during activation by using
2-NBDG, Bodipy FL C16, and Bodipy staining; we found that
activated ILC3s profoundly induced the extracellular glucose
uptake, lipid uptake, and cellular lipid content compared with
the resting cells (Fig. 5 A). Furthermore, transcriptomes of
resting and activated ILC3s were examined for the expression of
metabolic genes. ILC3 stimulation significantly increased ex-
pression of mTORC1 pathway genes (Fig. 5 B). Moreover, we
observed a coordinate increase in expression of genes encoding:
(a) key glycolytic mediators, such as Slc2A1 (Glut1), Hk1 and Hk2
(hexokinases), and Hif1a (Fig. 5 C); (b) proteins involved in lip-
ogenesis (e.g., Acaca, Fasn, Hmgcs1, and Gps1) and lipid uptake
(e.g., Npc1l1, Ldlr, Slc27a2, and Slc27a4; Fig. 5 D); and (c) proteins
involved in mitochondrial respiratory function and ROS gener-
ation (Atp5b, Atp5g1, Cox17, Cox5b, Cox8a, Cycs, Sdhb, Sdhc, Sdhd,
Ndufa6, and Ndufb8; Fig. 5 E). To directly determine whether
mTORC1 impacts human ILC3 effector functions, tonsillar ILC3s
were stimulated with IL-23 plus IL-1β in the presence or absence
of Rapa, PX, Rot/Ant, or DMM. Inhibition of mTORC1-HIF1α
signaling and mitochondrial-derived ROS profoundly inhibited
ILC3 production of IL-22 (Fig. 5 F), as well as proliferation
(Fig. 5 G), which indicates that cytokine-induced activation
of human ILC3s, like mouse ILC3s, relies on metabolic
reprogramming.
Concluding remarks
Previous analyses of the metabolic programs employed by Th17
and T reg cells have shown a clear dichotomy. Th17s rely on the
mTORC1-HIF1α pathway, which promotes glycolysis and di-
rectly induces RORγt expression (Delgoffe et al., 2009, 2011;
Dang et al., 2011; Michalek et al., 2011; Shi et al., 2011;
Kurebayashi et al., 2012; Gerriets et al., 2015). T reg cells rely on
lipid oxidation and generation of mROS in mitochondria
in the presence or absence of Rapa or PX, assessed by flow cytometry. A representative histogram and quantification of mean fluorescence intensity (MFI) are
shown. (J) Expression of IL-17A and IL-22 in MNK3 treated as in G, measured by flow cytometry. (K) Expression of IL-17A and IL-22 in lamina propria ILC3
stimulated with IL-1β + IL-23 for 3 h without or with Rapa or PX. Ctrl, control. (L) Percentage of BrdU+ MNK3 stimulated for 16 h with or without Rapa and PX,
measured by flow cytometry. Data in A–J and L are from one experiment representative of two to three independent experiments, and data in K are pooled
from three independent experiments (mean ± SEM of n = 3–8; one-way ANOVA or Student’s t test). gMFI, geometric MFI.
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Figure 4. mTORC1 signaling in ILC3 induces mROS. (A) Basal OCR in MNK3 stimulated (Stim) with IL-1β + IL-23 for 16 h with or without Rapa or PX.
(B) DCFDA and MitoSOX staining of MNK3 stimulated with IL-1β + IL-23 for 16 h with or without Rapa, NAC, or Rot/Ant, respectively, assessed by flow
cytometry (dotted line indicates unstimulated controls). (C) DCFDA and MitoSOX staining of lamina propria ILC3 stimulated with IL-1β + IL-23 for 3 h in the
presence or absence of Rapa, NAC, or Rot/Ant, assessed by flow cytometry (n = 4). Bar graphs showMFI relative to that of naive lamina propria ILC3. (D and E)
Expression of HIF1α and RORγt in MNK3 stimulated with IL-1β + IL-23 for 6 h with or without Rapa or PX, assessed by flow cytometry. Representative
histograms and quantification of MFI are shown. (F) IL-17A and IL-22 intracellular content of MNK3, unstimulated or stimulated with IL-1β + IL-23 with or
without NAC or Rot/Ant, assessed by flow cytometry. (G) Percentage of Ki67+ MNK3 stimulated with IL-1β + IL-23 for 16 h with or without Rapa or PX, assessed
by flow cytometry. (H and I)HIF1α and RORγt content of MNK3 stimulatedwith IL-1β + IL-23 for 6 hwith or without DMM, assessed by flow cytometry. Graph bars
indicate MFI relative to unstimulated MNK3. (J) Ki67 staining of MNK3 stimulated with IL-1β + IL-23 for 16 h in the presence or absence of DMM, assessed by flow
Di Luccia et al. Journal of Experimental Medicine 2237
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(Michalek et al., 2011; Gerriets et al., 2015). Our study demon-
strates that although ILC3s are the innate counterparts of Th17s,
they have adopted quite distinct metabolic strategies to cope
with environmental cues. During ILC3 activation, mTORC1-
HIF1α signaling reprograms the metabolism toward glycolysis
and augments RORγt expression, as observed in Th17s. Of note,
it has been shown that lower oxygen conditions can elevate the
activity of the mTORC1-HIF1α axis to promote Th17 differenti-
ation (Ikejiri et al., 2012); thus, a hypoxic environment might
also promote ILC3 development. Furthermore, de novo fatty acid
synthesis is evident in activated ILC3s; this is a metabolic feature
that distinguishes Th17 cells from T reg cells (Berod et al., 2014).
However, the metabolic adaptation of ILC3s diverges from that
of Th17s in their use of mitochondrial metabolism and the im-
pact of mROS. Th17s maintain low levels of mitochondrial me-
tabolism and generate very little mROS, which can deviate CD4
T cell differentiation toward T reg cells by inhibiting pyruvate
dehydrogenase kinase, a key regulator of glycolysis (Gerriets
et al., 2015). In contrast, ILC3s produce mROS, which stabilizes
HIF1α activity, enhances RORγt expression, and ultimately
promotes effector functions.
ILC3s’ reliance on mROS is reminiscent of the metabolic
changes observed in LPS-activated macrophages (Mills et al.,
2016, 2017). In these cells, glycolysis is associated with a break
in the Krebs cycle and activation of SDH; this results in the
generation of mROS, which activates HIF1α and glycolysis.
Further supporting the parallel between ILC3s and LPS-
activated macrophages, we found that SDH inhibition by DMM
dampened ILC3 activation. The importance of mROS in ILC3
activation is also consistent with previous studies showing that
mROS signaling is needed for T cell activation, at least during
antigen-specific expansion (Sena et al., 2013). Moreover, the
mTORC1-HIF1α pathway has been shown to promote mito-
chondrial metabolism in various contexts (Semenza, 2011;
Lamming and Sabatini, 2013; Morita et al., 2013). Why mROS
enhance ILC3 functions but deviate CD4 T cell differentiation
away from Th17s and toward T reg cells remains unclear. It is
noteworthy that ILCs include effector subsets corresponding to
TH1, TH2, and Th17 cells but lack a regulatory subset expressing
FoxP3. Thus, we envision that while ILC3s use and integrate
both glycolytic and mROS signals to boost effector functions,
CD4 T cells have adopted glycolysis and mROS as separate
pathways to control the balance between Th17 and T reg cells.
Future studies will examine the mROS downstream targets that




B6.129S7-Rag1tm1Mom/J (Rag1−/−; #002216) and B6.Cg-Rptortm1.1Dmsa/J
(Rptorfl/fl; #013188) mice were purchased from the Jackson
Laboratory. Rorc-Cre mice have been described (Eberl and
Littman, 2004). All mice were bred and maintained in specific
pathogen–free facilities under protocols approved by the institu-
tional animal care at Washington University School of Medicine
and were used at 8–10 wk of age.
C. rodentium infection
8–10-wk-old age- and gender-matched mice were orally ad-
ministered 2 × 109 C. rodentium, strain DBS100 (ATCC), as pre-
viously described (Cella et al., 2009). Body weight of mice was
measured until day 7. For Rapa injection, mice were injected i.p.
with 200 µl of Rapa (5 mg/kg body weight) or DMSO vehicle
before infection.
Tissue dissociation
Cells were isolated from the small intestine lamina propria by
treating tissue with EDTA (Corning), digesting with Collagenase
IV (Sigma-Aldrich), and then subjecting digests to density gra-
dient centrifugation.
Cell culture and activation
MNK3 cells or single-cell preparations of small intestine lamina
propria were cultured in complete RPMI (Corning) with or
without a combination of IL-1β (10 ng/ml) and IL-23 (10 ng/ml)
in the presence or absence of 20 nM Rapa (Millipore), 20 µM PX
(Selleckchem), 0.1 µM Rot (Sigma-Aldrich) + 1 µM Ant (Sigma-
Aldrich), 5 mM NAC (Sigma-Aldrich), 50 µM MitoTEMPO
(Sigma-Aldrich), 20 mM DMM (Sigma-Aldrich), 1 mM 2-DG
(Sigma-Aldrich), and 200 µM ETO (Cayman). Brefeldin A (BD
GolgiPlug) was added to cultures 3 h before analysis of intra-
cellular cytokines.
Flow cytometry
Rat anti-human/mouse RORγt (AFKJS-9), rat anti-mouse Eomes
(Dan11mag), rat anti-mouse/rat Ki67 (SolA15), anti-mouse NK1.1
(PK136), anti-mouse CD3 (145-2C11), anti-mouse CD5 (53–7.3),
rat anti-mouse CD19 (1D3), and rat anti-mouse IL-22 (1H8PWSR)
were purchased from eBioscience. Rat anti-mouse IL-17A (TC11-
18H10), rat anti-mouse Thy1.2 (30-H12), rat anti-mouse CD196
(CCR6; 140706), and BrdU were purchased from BD Biosciences.
Rat anti-mouse CD45 (30-F11) was purchased from BioLegend.
Anti-phospho-p70 S6K (pS6K) and anti-phospho-4EBP1
(p4EBP1) were purchased from Cell Signaling. Anti-human/
mouse HIF1α (241812) antibody was purchased from R&D Sys-
tems. Anti-human/mouse Glut1 antibody was purchased from
Metafora. Dead cells were excluded using a Live/Dead Fixable
Cell Stain Kit (Thermo Fisher Scientific). Intracellular staining
was either the BD Biosciences Fixation/Permeabilization So-
lution Kit or eBioscience Transcription Factor staining kit. For
uptake of 2-NBDG (10 µg/ml; Invitrogen), Bodipy (500 µg/ml;
Invitrogen), and Bodipy FL C16 (1 µM; Invitrogen), was per-
formed by incubating cells in RPMI medium for 30–60 min at
cytometry. Bar graphs indicate fold increase relative to unstimulated MNK3 (dotted line). (K) Expression of IL-17A and IL-22 by MNK3, unstimulated or stimulated
with IL-1β + IL-23 for 6 h with or without DMM. Data in A, B, and D–K are from one experiment representative of two or three independent experiments, and data
in C are pooled from two independent experiments (mean ± SEM of n = 2–4; one-way ANOVA or Student’s t test).
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37°C and measured by flow cytometry. Detection of ROS using
DCFDA (20 µM; Abcam) was performed by incubating cells in
RPMI medium 1 h at 37°C or using MitoSOX (5 µM; Invitrogen) by
incubating cells in HBSS for 10 min at 37°C and measuring by flow
cytometry. Data were acquired on a FACSCanto II flow cytometer
(BD Biosciences) and analyzed with FlowJo v.9.5.2 (TreeStar).
Metabolism assays
For real-time analysis of ECARs and OCRs, MNK3 cells (1.5 × 105
cells/well) were analyzed using an XF-96 Extracellular Flux Ana-
lyzer (Seahorse Bioscience) as described in detail previously (Huang
et al., 2014). ATP assays weremeasuredwith an ATP Determination
Kit according to the manufacturer’s instructions (Invitrogen).
Figure 5. Human ILC3 activation requires mTOR-mediated metabolic reprogramming. (A) Uptake of 2-NBDG, Bodipy FL C16, and Bodipy in human ILC3s
unstimulated or stimulated with IL-1β + IL-23 for 16 h, measured by flow cytometry. (B–E) Heatmaps of the expression of genes controlling mTOR signaling,
glycolysis, lipid metabolism, and mitochondrial function in human tonsillar ILC3, unstimulated (Unstim) or stimulated (Stim) with IL-1β + IL-23 for 16 h.
(F) Amount of IL-22 released in culture supernatant by human ILC3, unstimulated or stimulated with IL-1β + IL-23 for 72 h in the presence or absence of Rapa,
PX, Rot/Ant, or DMM (n = 2). (G) Ki67 staining of ILC3 stimulated with IL-1β + IL-23 for 72 h as in E, assessed by flow cytometry (mean ± SEM of n = 2; one-way
ANOVA or Student’s t test). Graph bars indicate fold increase relative to unstimulated human ILC3s. gMFI, geometric MFI.
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Cell fractionation and immunoblotting
Cells were lysed in buffer containing 1% Triton X-100 and
0.1% SDS with protease and phosphatase inhibitors. Anti-
HIF1α (D1S7W; Cell Signaling), anti-RORγt (Biorbyt), and
anti–β-actin (Cell Signaling) were used and detected with
peroxidase-linked secondary antibody followed by ECL
Western Blotting Detection Reagents (Thermo Fisher
Scientific).
Human samples
Cells were sorted from two to three pooled donors and then
stimulated with a combination of human IL-1β (10 ng/ml), IL-23
(10 ng/ml), and IL-15 (25 ng/ml) at 37°C for 16 h or as indicated.
For microarray analysis, RNA was isolated (RNeasy Plus Micro
Kit; Qiagen), amplified, and hybridized to the Affymetrix Hu-
man Gene (v.1.0) ST arrays. Data were analyzed with Gene-
Pattern software (Broad Institute) and Ingenuity Pathway
Analysis (Qiagen) as previously described (Robinette et al.,
2015). Secretion of IL-22 by human ILC3 (105) was collected
and measured with a human IL-22 Quantikine ELISA kit ac-
cording to the manufacturer’s instructions (R&D Systems). All
human studies were conducted under the approval of Institu-
tional Review Boards of Washington University (IRB#03-1214).
Microarray data are deposited in the Gene Expression Omnibus
database under accession no. GSE132843.
Online supplemental material
Fig. S1 shows that Rapa treatment impairs ILC3s’ response to a
bacterial infection. Fig. S2 shows the expression of RORγt and
HIF1α in MNK3s by immunoblotting. Fig. S3 indicates that
mROS supports ILC3 function.
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